Abstract:Rationale: Short QT syndrome (SQT) is a rare but arrhythmogenic disorder featured by shortened ventricular repolarization and a propensity toward life-threatening ventricular arrhythmias and sudden cardiac death. Objective: This study aimed to investigate the single-cell mechanism of SQT using patient-specific and gene-corrected induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Methods and Results: One SQT patient carrying missense mutation T618I in potassium voltage-gated channel subfamily H member 2 (KCNH2) was recruited as well as 2 healthy control subjects in this study. Control and SQT patient-specific iPSCs were generated from skin fibroblasts using nonintegrated Sendai virus. The KCNH2 T618I mutation was corrected by genome editing in SQT iPSC lines to generate isogenic controls. All iPSCs were differentiated into iPSC-CMs using monolayer-based differentiation protocol. SQT iPSC-CMs exhibited abnormal action potential phenotype featured by shortened action potential duration and increased beat-beat interval variability, when compared with control and gene-corrected iPSC-CMs. Furthermore, SQT iPSC-CMs showed KCNH2 gain-of-function with increased rapid delayed rectifying potassium current (IKr) density and enhanced membrane expression. Gene expression profiling of iPSC-CMs exhibited a differential cardiac ion-channel gene expression profile of SQT. Moreover, QTc of SQT patient and action potential durations of SQT iPSC-CMs were both normalized by quinidine, indicating that quinidine is beneficial to KCNH2 T618I of SQT. Importantly, shortened action potential duration phenotype observed in SQT iPSC-CMs was effectively rescued by a short-peptide scorpion toxin BmKKx2 with a mechanism of targeting KCNH2. Conclusions: We demonstrate that patient-specific and gene-corrected iPSC-CMs are able to recapitulate single-cell phenotype of SQT, which is caused by the gain-of-function mutation KCNH2 T618I. These findings will help elucidate the mechanisms underlying SQT and discover therapeutic drugs for treating the disease by using peptide toxins as lead compounds.

An Induced Pluripotent Stem Cell Line (Shehi002-a (5426))from a Patient of Long QT Syndrome Type 8 with C.2573g>a Mutation in the Gene CACNA1C.

Generation of an Induced Pluripotent Stem Cell Line from a Long QT Syndrome Patient Carrying KCNH2/1956C > A Mutation.

Generation of an Induced Pluripotent Stem Cell Line (Zjulli003-A) from a Hypertrophic Cardiomyopathy Patient Carrying MYH7/c.4384G > A Mutation

Generation of an Induced Pluripotent Stem Cell Line from a Brugada Syndrome Patient Carrying SCN5A/c.3118G>C Mutation

Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome

Genome Editing of Isogenic Human Induced Pluripotent Stem Cells Recapitulates Long QT Phenotype for Drug Testing.

Generation of Three Ipsc Lines (Xachi007-A, XACHi008-A, XACHi009-A) from a Chinese Family with Long QT Syndrome Type 5 with Heterozygous C.226g>a (p.d76n) Mutation in KCNE1gene.

Generation of Induced Pluripotent Stem Cells (ipscs) from a Chinese Infant (Xachi015-A) with Type 2 Long QT Syndrome Carrying the Heterozygous Mutation C.1814c>t(p.p605l) in KCNH2.

Establishment of an Induced Pluripotent Stem Cell Line (Zjulli004-A) from a Hypertrophic Cardiomyopathy Patient Carrying MYBPC3/c.3764C>A Mutation

Establishment of a human-induced pluripotent stem cell line from a long QT syndrome type 2 patient harboring a KCNH2 mutation

Generation of KCNH2 heterozygous knockout induced pluripotent stem cell (iPSC) line (Long and Short QT Syndrome)

Generation of Induced Pluripotent Stem Cell Line, ZJUCHi002-A, from Charcot-Marie-Tooth Disease Type 2A (CMT2A) Patient with a Mutation of C.752c>t in MFN2

Induced pluripotent stem cell model from urine epithelial cells of patient with long QT syndrome

Characterization of the CACNA1C-R518C Missense Mutation in the Pathobiology of Long-QT Syndrome Using Human Induced Pluripotent Stem Cell Cardiomyocytes Shows Action Potential Prolongation and L-Type Calcium Channel Perturbation.

Establishment of an Induced Pluripotent Stem Cell Line from a Patient with CHARGE Syndrome Carrying a CHD7 (p.l1151gfs*17) Mutation

Induced pluripotent stem cells (SHCDNi006-A cells) isolated from the peripheral blood mononuclear cells of a five-month-old Chinese girl with the heterozygous missense mutation (c.2800 G>A) in the KCNT1 gene

Generation of a Human Charcot-Marie-Tooth Disease Type 1B (CMT1B) Ipsc Line, ZJUCHi001-A, with a Mutation of C.292c>t in MPZ.

Generating a Human Induced Pluripotent Stem Cell Line (Xachi018-A) from a Timothy Syndrome Infant Carrying Heterozygous CACNA1C C.1216g>a (p.g406r) Mutation

Generation of induced pluripotent stem cells (iPSCs) from an infant with catecholaminergic polymorphic ventricular tachycardia carrying the double heterozygous mutations A1855D in RyR2 and Q1362H in SCN10A.

Establishment and characterization of ZJUCHi003: an induced pluripotent stem cell line from a patient with Temple–Baraitser/Zimmermann–Laband syndrome carrying KCNH1 c.1070G > A (p.R357Q) variant

Generation and Characterization of Ipsc Lines (BCH001) from a Boy with Intron 14 Mutation in the Ret Proto-Oncogene (RET) Gene.